ClinicalTrials.gg
CompletedNCT01033071Updated Feb 7, 2012Results posted

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Azilsartan medoxomil and chlorthalidone in Essential Hypertension, sponsored by Takeda. Completed at 94 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-07.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,071
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.

Enrollment
4th of 11
1,071 · median 837
Started
2010
the only one that year
Phase 3
10 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
11 of 11
Takeda

Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 10 in phase 3, and was the 9th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing azilsartan medoxomil in Essential Hypertension as a file.
02

Study summary

The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.

Read the detailed description

According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully.

Treatment algorithms for essential hypertension commonly include thiazides or thiazide-like diuretics, either alone or as part of combination treatment. Chlorthalidone is a commercially available, orally administered thiazide-type diuretic agent.

TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker developed by Takeda to treat participants with essential hypertension.

This study will compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone (TAK-491CLD) fixed-dose combination to olmesartan medoxomil plus hydrochlorothiazide fixed-dose combination.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Hypertensive
  • Blood Pressure, High
  • Cardiovascular disease
  • Vascular Disease
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg.
  2. Females of who are sexually active agree to routinely use adequate from Screening through 30 days after the last administered study drug dose.
  3. Has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be .
  4. Is willing to discontinue current antihypertensive medications on Day -21 or Day -28 if the participant is on amlodipine or chlorthalidone.

Exclusion criteria

Exclusion Criteria:

  1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg on Day -1.
  2. Has a baseline 24-hour ambulatory blood pressure monitoring reading of insufficient quality.
  3. Works a night (third) shift.
  4. Has an upper arm circumference less than 24 cm or greater than 42 cm.
  5. Has secondary hypertension of any etiology.
  6. Has a recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  7. Has cardiac conduction defects.
  8. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  9. Has severe renal dysfunction or disease.
  10. Has known or suspected unilateral or bilateral renal artery stenosis.
  11. Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
  12. Has poorly-controlled diabetes mellitus at Screening.
  13. Has hypokalemia or hyperkalemia.
  14. Has an or aspartate aminotransferase level of greater than 2.5 times the , active liver disease, or jaundice.
  15. Has any other known serious disease or condition that would compromise safety, might affect , or make it difficult to successfully manage and follow the participant according to the protocol.
  16. Has known to angiotensin II receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds.
  17. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,071 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Experimental
    Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Active comparator
    Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD

    Drug: Olmesartan medoxomil and hydrochlorothiazide

Interventions

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.

    Also known as: azilsartan medoxomil plus chlorthalidone, TAK-491CLD

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.

    Also known as: azilsartan medoxomil plus chlorthalidone, TAK-491CLD

  • DrugOlmesartan medoxomil and hydrochlorothiazide

    Drug pages: Olmesartan Medoxomil · Hydrochlorothiazide

    Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks.

    Also known as: Benicar HCT®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.

    The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 12.

Secondary outcomes

  1. Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.

    The change in sitting trough clinic systolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.

    Time frame: Baseline, Week 4 and Week 8.

  2. Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.

    The change in sitting trough clinic diastolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average (arithmetic mean) of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.

    Time frame: Baseline, Week 4, Week 8 and Week 12.

  3. Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

    The change in trough systolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 12.

  4. Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

    The change in trough diastolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 12.

  5. Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 12.

  6. Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 12.

  7. Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive).

    Time frame: Baseline and Week 12.

  8. Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive).

    Time frame: Baseline and Week 12.

  9. Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

    The change in the mean nighttime (12am to 6am) systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive).

    Time frame: Baseline and Week 12.

  10. Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

    The change in the mean nighttime (12am to 6am) diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive).

    Time frame: Baseline and Week 12.

  11. Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.

    The change in the mean 12 hour systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements.

    Time frame: Baseline and Week 12.

  12. Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.

    The change in the mean 12 hour diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements.

    Time frame: Baseline and Week 12.

  13. Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.

    The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour.

    Time frame: Baseline and Week 12.

  14. Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.

    The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour.

    Time frame: Baseline and Week 12.

  15. Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.

    Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the non-missing values of the 3serial trough sitting systolic blood pressure measurements.

    Time frame: Baseline, Week 4, Week 8 and Week 12.

  16. Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.

    Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.

    Time frame: Baseline, Week 4, Week 8 and Week 12.

  17. Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.

    Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the non-missing values of the 3 serial trough sitting blood pressure measurements.

    Time frame: Baseline, Week 4, Week 8 and Week 12.

07

Results

Posted Feb 7, 2012

Participant flow

Participants enrolled at 130 investigative sites in Canada and the United States from 08 December 2009 to 04 November 2010.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Started355352364
Completed300275317
Not completed557747
Withdrew: Adverse event285126
Withdrew: Protocol violation021
Withdrew: Lost to follow-up455
Withdrew: Withdrawal by subject171411
Withdrew: Lack of efficacy011
Withdrew: Other643

Outcome measures

PrimaryChange From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.-42.5 ± 0.81-44.0 ± 0.83-37.1 ± 0.80
Statistical analysis
  • Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Overall Type 1 error rate of 0.05 controlled using 'Closed Testing' principle (hypothesis of "all treatment groups equal" first tested at 0.05 significance level; upon rejection of this hypothesis, pairwise comparison was tested at the 0.05 level.) · Mean difference (final values): -5.3 · 95% CI -7.6 to -3.1
  • Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Overall Type 1 error rate of 0.05 controlled using 'Closed Testing' principle (hypothesis of "all treatment groups equal" first tested at 0.05 significance level; upon rejection of this hypothesis, pairwise comparison was tested at the 0.05 level.) · Mean difference (final values): -6.9 · 95% CI -9.2 to -4.6
SecondaryChange From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in sitting trough clinic systolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=343; n=330; n=352)-34.7 ± 0.77-36.7 ± 0.79-29.7 ± 0.76
Week 8 (n=344; n=330; n=353)-39.1 ± 0.78-39.4 ± 0.80-33.5 ± 0.77
SecondaryChange From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.

The change in sitting trough clinic diastolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average (arithmetic mean) of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.

Time frame:
Baseline, Week 4, Week 8 and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=343; n=330; n=352)-14.9 ± 0.46-15.8 ± 0.47-11.7 ± 0.45
Week 8 (n=344; n=330; n=353)-17.0 ± 0.48-17.7 ± 0.49-13.9 ± 0.48
Week 12 (n=344; n=330; n=354)-18.8 ± 0.47-20.5 ± 0.48-16.4 ± 0.46
SecondaryChange From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in trough systolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.-32.9 ± 0.86-34.9 ± 0.90-25.9 ± 0.85
Statistical analysis
  • Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Tested at the 0.05 significance level.) · Mean difference (final values): -7.0 · 95% CI -9.4 to -4.7
  • Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Tested at the 0.05 significance level.) · Mean difference (final values): -9.0 · 95% CI -11.5 to -6.6
SecondaryChange From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in trough diastolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.-19.8 ± 0.55-20.2 ± 0.57-16.0 ± 0.54
SecondaryChange From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.-33.9 ± 0.76-36.3 ± 0.79-27.5 ± 0.75
Statistical analysis
  • Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Tested at the 0.05 significance level.) · Mean difference (final values): -6.4 · 95% CI -8.5 to -4.3
  • Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Tested at the 0.05 significance level.) · Mean difference (final values): -8.8 · 95% CI -11.0 to -6.7
SecondaryChange From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.-19.4 ± 0.45-20.7 ± 0.46-16.2 ± 0.44
SecondaryChange From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive).

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.-35.3 ± 0.80-37.9 ± 0.84-28.8 ± 0.79
SecondaryChange From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive).

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.-20.1 ± 0.48-21.8 ± 0.50-17.0 ± 0.47
SecondaryChange From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in the mean nighttime (12am to 6am) systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive).

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.-29.6 ± 0.78-31.8 ± 0.81-23.9 ± 0.77
SecondaryChange From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in the mean nighttime (12am to 6am) diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive).

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.-17.5 ± 0.48-18.0 ± 0.50-14.0 ± 0.48
SecondaryChange From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.

The change in the mean 12 hour systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.-36.2 ± 0.86-38.8 ± 0.89-29.7 ± 0.85
SecondaryChange From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.

The change in the mean 12 hour diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.-20.4 ± 0.51-22.2 ± 0.53-17.5 ± 0.50
SecondaryChange From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.

The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
0 to 1 Hour (n=232; n=212; n=237)-33.6 ± 0.96-36.2 ± 1.00-26.8 ± 0.95
1 to 2 Hour (n=232; n=214; n=238)-33.4 ± 0.98-36.4 ± 1.02-27.5 ± 0.97
2 to 3 Hour (n=232; n=214; n=238)-36.7 ± 1.02-39.3 ± 1.06-30.0 ± 1.00
3 to 4 Hour (n=232; n=214; n=238)-36.6 ± 1.07-40.3 ± 1.12-29.6 ± 1.06
4 to 5 Hour (n=232; n=214; n=238)-36.8 ± 1.07-40.8 ± 1.11-30.1 ± 1.06
5 to 6 Hour (n=232; n=214; n=238)-37.2 ± 1.02-41.2 ± 1.06-31.5 ± 1.00
6 to 7 Hour (n=232; n=214; n=238)-36.3 ± 1.04-38.6 ± 1.08-29.8 ± 1.02
7 to 8 Hour (n=232; n=214; n=238)-37.2 ± 1.02-38.5 ± 1.06-29.7 ± 1.00
8 to 9 Hour (n=232; n=214; n=238)-37.3 ± 1.02-38.1 ± 1.06-30.5 ± 1.01
9 to 10 Hour (n=232; n=214; n=238)-36.9 ± 0.99-38.0 ± 1.04-30.8 ± 0.98
10 to 11 Hour (n=232; n=214; n=238)-36.1 ± 1.02-37.6 ± 1.06-29.4 ± 1.01
11 to 12 Hour (n=232; n=214; n=238)-35.2 ± 1.01-38.2 ± 1.05-29.3 ± 1.00
12 to 13 Hour (n=232; n=214; n=238)-34.8 ± 1.05-36.2 ± 1.09-27.7 ± 1.04
13 to 14 Hour (n=232; n=214; n=238)-34.1 ± 1.06-35.3 ± 1.11-26.4 ± 1.05
14 to 15 Hour (n=232; n=214; n=238)-33.4 ± 1.06-35.0 ± 1.10-26.2 ± 1.04
15 to 16 Hour (n=232; n=214; n=238)-30.9 ± 0.99-32.9 ± 1.03-25.3 ± 0.97
16 to 17 Hour (n=232; n=214; n=238)-29.6 ± 0.94-31.1 ± 0.98-24.5 ± 0.93
17 to 18 Hour (n=231; n=214; n=238)-28.5 ± 0.93-30.8 ± 0.97-23.1 ± 0.92
18 to 19 Hour (n=232; n=214; n=238)-29.5 ± 0.90-31.9 ± 0.94-24.3 ± 0.89
19 to 20 Hour (n=232; n=214; n=238)-29.7 ± 0.89-32.5 ± 0.93-23.5 ± 0.88
20 to 21 Hour (n=232; n=214; n=238)-28.2 ± 0.94-31.2 ± 0.98-23.0 ± 0.92
21 to 22 Hour (n=232; n=214; n=238)-30.6 ± 0.95-32.8 ± 0.99-24.6 ± 0.93
22 to 23 Hour (n=232; n=214; n=238)-32.9 ± 0.94-34.0 ± 0.98-25.9 ± 0.92
23 to 24 Hour (n=232; n=214; n=238)-33.1 ± 0.92-35.8 ± 0.96-26.1 ± 0.91
SecondaryChange From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.

The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour.

Time frame:
Baseline and Week 12.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
0 to 1 Hour (n=232; n=212; n=237)-18.2 ± 0.59-20.4 ± 0.62-15.2 ± 0.59
1 to 2 Hour (n=232; n=214; n=238)-18.8 ± 0.65-20.9 ± 0.67-15.9 ± 0.64
2 to 3 Hour (n=232; n=214; n=238)-21.2 ± 0.66-23.4 ± 0.69-17.7 ± 0.65
3 to 4 Hour (n=232; n=214; n=238)-20.8 ± 0.69-23.7 ± 0.72-18.2 ± 0.68
4 to 5 Hour (n=232; n=214; n=238)-21.7 ± 0.67-23.7 ± 0.70-17.9 ± 0.66
5 to 6 Hour (n=232; n=214; n=238)-20.9 ± 0.67-23.6 ± 0.70-19.0 ± 0.66
6 to 7 Hour (n=232; n=214; n=238)-20.8 ± 0.65-22.0 ± 0.67-18.0 ± 0.64
7 to 8 Hour (n=232; n=214; n=238)-20.5 ± 0.66-21.9 ± 0.69-17.7 ± 0.65
8 to 9 Hour (n=232; n=214; n=238)-20.7 ± 0.67-21.5 ± 0.69-17.9 ± 0.66
9 to 10 Hour (n=232; n=214; n=238)-21.0 ± 0.66-21.9 ± 0.68-18.3 ± 0.65
10 to 11 Hour (n=232; n=214; n=238)-19.7 ± 0.67-20.7 ± 0.70-16.7 ± 0.66
11 to 12 Hour (n=232; n=214; n=238)-19.3 ± 0.69-21.2 ± 0.72-17.0 ± 0.68
12 to 13 Hour (n=232; n=214; n=238)-19.2 ± 0.73-20.3 ± 0.76-16.0 ± 0.72
13 to 14 Hour (n=232; n=214; n=238)-19.6 ± 0.72-19.5 ± 0.75-15.3 ± 0.71
14 to 15 Hour (n=232; n=214; n=238)-18.9 ± 0.72-19.7 ± 0.75-15.4 ± 0.71
15 to 16 Hour (n=232; n=214; n=238)-17.8 ± 0.65-18.6 ± 0.68-14.5 ± 0.65
16 to 17 Hour (n=232; n=214; n=238)-17.2 ± 0.65-16.9 ± 0.68-13.9 ± 0.64
17 to 18 Hour (n=231; n=214; n=238)-16.6 ± 0.64-17.1 ± 0.66-13.2 ± 0.63
18 to 19 Hour (n=232; n=214; n=238)-17.4 ± 0.65-18.1 ± 0.67-14.3 ± 0.64
19 to 20 Hour (n=232; n=214; n=238)-17.8 ± 0.60-18.5 ± 0.63-13.8 ± 0.60
20 to 21 Hour (n=232; n=214; n=238)-16.7 ± 0.64-18.4 ± 0.67-13.9 ± 0.63
21 to 22 Hour (n=232; n=214; n=238)-17.8 ± 0.66-18.5 ± 0.69-14.7 ± 0.65
22 to 23 Hour (n=232; n=214; n=238)-19.5 ± 0.62-19.6 ± 0.65-15.6 ± 0.62
23 to 24 Hour (n=232; n=214; n=238)-20.2 ± 0.60-21.0 ± 0.62-16.4 ± 0.59
SecondaryPercentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.

Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the non-missing values of the 3serial trough sitting systolic blood pressure measurements.

Time frame:
Baseline, Week 4, Week 8 and Week 12.
Reported as:
Number · percentage of participants
Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.
percentage of participantsAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=343; n=330; n=352)87.890.079.8
Week 8 (n=344; n=330; n=353)93.392.485.6
Week 12 (n=344; n=330; n=354)93.094.289.3
SecondaryPercentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.

Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.

Time frame:
Baseline, Week 4, Week 8 and Week 12.
Reported as:
Number · percentage of participants
Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
percentage of participantsAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=343; n=330; n=352)89.289.785.2
Week 8 (n=344; n=330; n=353)90.790.987.8
Week 12 (n=344; n=330; n=354)94.595.891.5
SecondaryPercent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the non-missing values of the 3 serial trough sitting blood pressure measurements.

Time frame:
Baseline, Week 4, Week 8 and Week 12.
Reported as:
Number · percent of participants
Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
percent of participantsAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=343; n=330; n=352)81.384.874.4
Week 8 (n=344; n=330; n=353)88.187.381.0
Week 12 (n=344; n=330; n=354)91.392.484.7

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD—1/355 (0.3%)141/355 (39.7%)
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD—10/352 (2.8%)144/352 (40.9%)
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD—8/364 (2.2%)94/364 (25.8%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
HypotensionVascular disorders0/3553/3520/364
DehydrationMetabolism and nutrition disorders0/3552/3520/364
SyncopeNervous system disorders0/3552/3520/364
AnaemiaBlood and lymphatic system disorders0/3551/3520/364
ArrhythmiaCardiac disorders0/3551/3520/364
Cardiac failure congestiveCardiac disorders0/3551/3520/364
VertigoEar and labyrinth disorders0/3551/3520/364
VomitingGastrointestinal disorders0/3551/3520/364
Non-cardiac chest painGeneral disorders1/3551/3520/364
Lobar pneumoniaInfections and infestations0/3551/3520/364
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Blood creatinine increasedInvestigations66/35578/35234/364
DizzinessNervous system disorders41/35558/35229/364
FatigueGeneral disorders33/35514/35216/364
HeadacheNervous system disorders19/35513/35226/364
Blood uric acid increasedInvestigations19/35517/35212/364

Baseline characteristics

Age Continuous
Age Continuous(years)Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Mean56.4 ± 10.4956.7 ± 10.0756.7 ± 10.8656.6 ± 10.47
Age, Customized
Age, Customized(participants)Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
<45 years463346125
Between 45 to 64 years235241234710
≥65 years747884236
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Female132151159442
Male223201205629
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Hispanic or Latino28363498
Not Hispanic or Latino248241251740
Unknown or Not Reported797579233
Race (NIH/OMB)
Race (NIH/OMB)(participants)Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
American Indian or Alaska Native25512
Asian13111135
Native Hawaiian or Other Pacific Islander0123
Black or African American808080240
White261258267786
More than one race1214
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
United States276277285838
Canada797579233
Weight
Weight(kg)Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Mean92.34 ± 20.29691.47 ± 20.98790.83 ± 18.59091.54 ± 19.960
Height
Height(cm)Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QDAzilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Mean171.2 ± 10.15169.3 ± 10.88169.4 ± 10.15170.0 ± 10.42

2 further baseline measures are reported on the registry.

08

Study locations

94 sites
  • Gulf Shores, Alabama, United States
  • Litchfield Park, Arizona, United States
  • Mesa, Arizona, United States
  • Scottsdale, Arizona, United States
  • Tucson, Arizona, United States
  • Buena Park, California, United States
  • Carmichael, California, United States
  • Greenbrae, California, United States
  • Irvine, California, United States
  • Paramount, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Spring Valley, California, United States
  • Wildomar, California, United States
  • Colorado Springs, Colorado, United States
  • Milford, Connecticut, United States
  • Waterbury, Connecticut, United States
  • Newark, Delaware, United States
  • Aventura, Florida, United States
  • Clearwater, Florida, United States
  • Deland, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Miami, Florida, United States
  • Ocala, Florida, United States
  • Plant City, Florida, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • West Palm beach, Florida, United States
  • Winter Haven, Florida, United States
  • Dunwoody, Georgia, United States
  • Roswell, Georgia, United States
  • Suwanee, Georgia, United States
  • Chicago, Illinois, United States
  • Melrose Park, Illinois, United States
  • Naperville, Illinois, United States
  • Avon, Indiana, United States
  • Indianapolis, Indiana, United States
  • Valparaiso, Indiana, United States
  • Crestview Hills, Kentucky, United States
  • Lexington, Kentucky, United States
  • Auburn, Maine, United States
  • Brockton, Massachusetts, United States
  • Hyannis, Massachusetts, United States
  • West Yarmouth, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • St Louis, Missouri, United States
  • St Peters, Missouri, United States
  • Henderson, Nevada, United States
  • Margate, New Jersey, United States
  • Wildwood Crest, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Glens Falls, New York, United States
  • Boiling Springs, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Willoughby Hills, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Yukon, Oklahoma, United States
  • Ashland, Oregon, United States
  • Portland, Oregon, United States
  • Bensalem, Pennsylvania, United States
  • Feasterville, Pennsylvania, United States
  • Lansdale, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Reading, Pennsylvania, United States
  • Tipton, Pennsylvania, United States
  • Cranston, Rhode Island, United States
  • Cumberland, Rhode Island, United States
  • Mt Pleasant, South Carolina, United States
  • Simpsonville, South Carolina, United States
  • Beaumont, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • North Richland Hills, Texas, United States
  • San Antonio, Texas, United States
  • Magna, Utah, United States
  • Manassas, Virginia, United States
  • Lakewood, Washington, United States
  • Port Orchard, Washington, United States
  • Madison, Wisconsin, United States
  • Menomonee Falls, Wisconsin, United States
  • Abbotsford, British Columbia, Canada
  • Powell River, British Columbia, Canada
  • Mount Pearl, Newfoundland and Labrador, Canada
  • Halifax, Nova Scotia, Canada
  • London, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Sarnia, Ontario, Canada
  • Vaughan, Ontario, Canada
  • Whitby, Ontario, Canada
  • Woodstock, Ontario, Canada
09

References and documents

Publications

  • Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug;60(2):310-8. doi: 10.1161/HYPERTENSIONAHA.111.188284. Epub 2012 Jun 18. PubMed 22710649 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Oct 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2009
First posted
Dec 16, 2009
Start
Jan 2010
Primary completionActual
Oct 2010
CompletionActual
Nov 2010
Results first posted
Feb 7, 2012
Last update
Feb 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01033071
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 16, 2009
Start date
Jan 2010
Primary completion
Oct 2010
Completion
Nov 2010
Results posted
Feb 7, 2012
Last update
Feb 7, 2012

Study contacts

Sr VP Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone

Start the discussion